For years, Squid Compression has helped ease the pain of patients in doctor's offices. Now, anyone can get the treatment on the go. Photo via squidgo.com

Houston company creates portable device that eases pain without the use of drugs

No pain, just gain

Many of the estimated 50 million Americans who suffer from chronic pain turn to drugs — including heavily abused opioids — to relieve their symptoms. Houston-based startup Portable Therapeutix LLC's drug-free solution to pain management seeks to put a dent in the market for prescription painkillers.

In 2018, Houston-based Portable Therapeutix introduced Squid Go, a portable device that's designed to ease the pain and swelling of sore joints and muscles. It's a follow-up to the company's Squid Compression, a pain management device launched in 2013 for patients at rehabilitation centers, hospitals, doctor's offices, and the like.

Squid Go enables consumers to apply two approaches — cold therapy and compression therapy — to relieving joint pain and swelling caused by arthritis, bouncing back from athletic activities, or recovering from an injury or surgery involving muscles and joints. Variations of the device can treat ankle, back, leg, knee, shoulder, or wrist pain.

To reap the benefits of Squid Go, a consumer uses the device for just 15 minutes. Squid Go — which combines a cold gel pack with proprietary compression technology — features special air pockets that inflate and deflate, gently massaging the body part needing treatment. That massaging boosts circulation and reduces swelling.

"Increased circulation brings more nutrient- and oxygen-rich blood to the area, promoting recovery," says Sam Stolbun, co-founder of Portable Therapeutix. "Meanwhile, [the] gentle compression also drives the pain-relieving cold from the gel pack deeper into the tissues to alleviate soreness and discomfort."

The coldness of the gel pack fights inflammation.

Stolbun says someone can take the lightweight, portable Squid Go device to the office, to the gym or anywhere else for on-the-go pain relief. It even can be used without the cold gel pack for compression-only therapy to improve circulation and decrease swelling. The Squid Go pump delivers about 15 treatments before it needs to be recharged.

Squid Compression received clearance from the U.S. Food and Drug Administration as a prescription-only device in 2013 and gained over-the-counter status in 2014. The consumer version, Squid Go, employs the same technology and operates the same way as Squid Compression, so a second FDA stamp of approval wasn't required.

Pricing for the heavy-duty Squid Compression system starts at $700. The consumer-friendly Squid Go system goes for $300 or $350, depending on its purpose. Users can buy extra wraps and gel packs to supplement the system.

Stolbun says he and co-founder Shai Schubert developed the Squid devices after realizing that existing pain-fighting cold packs provided only superficial relief, while water-based treatments were inconvenient and offered no compression advantages. Still other cold and compression therapies on the market are expensive and generally aren't covered by health insurance, he says.

Stolbun says that "it became apparent that a reasonably priced, well-made, portable, and effective pain relief and recovery device would meet a need for a broad range of consumers — from athletes to seniors."

Stolbun, a sports enthusiast and bakery mogul, and Schubert, a scientist and entrepreneur, established Portable Therapeutix in 2011.

The company's debut product, Squid Compression, still enjoys success, but Stolbun says the company has shifted its focus to Squid Go. Portable Therapeutix plans to pump up sales for Squid Go via its online presence, he says, as well as through physical therapists, sports trainers and other professionals who've used Squid Compression but want to offer the less pricey Squid Go model to their clients for in-home treatment.

Portable Therapeutix is backed by private investors; the amount of funding it has received isn't available. The company doesn't release revenue and profit figures.

Today, the company employs just one person in Houston but will add workers as its distribution pipeline expands, Stolbun says. Sales, marketing, and customer service representatives are scattered around the country. Stolbun, the CEO, is based in Houston, while Schubert, the chief technical officer, is based in Boston.

Portable Therapeutix relies, in part, on word-of-mouth praise to promote Squid Go. Among those hailing the device is Lee Ward of Houston, who describes himself as a competitive tennis player.

On the Squid Go website, Ward explains that he'd been suffering from progressively worsening tendonitis in his knees for a couple of years.

"I tried a number of remedies, including ice and gel packs, immediately following my tennis workout, but both remedies were ineffective and difficult to use," Ward says in his online testimonial.

He then discovered Squid Go and became a fan.

"The best thing about [Squid Go] is its ease of use. It provides a quick, effective treatment that makes it ideal for daily use by both the serious and recreational athlete," Ward says.

Smart tech

Courtesy of Squid Go

Squid Go combines a cold gel pack with proprietary compression technology and features special air pockets that inflate and deflate, gently massaging the body part needing treatment.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Nobel Prize nominee earns latest award for public health research

Prized Research

Houston vaccine scientist Dr. Peter Hotez can add one more prize to his shelf.

Hotez — dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, co-director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics — is no stranger to impressive laurels. In 2022, he was even nominated for a Nobel Peace Prize for his low-cost COVID vaccine.

His first big win of 2025 is this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project. The endeavor was born to help create a predictive disease atlas relating to climate disasters. Because the climate crisis has ushered in changes to the distribution of diseases, including dengue, chikungunya, Zika, Chagas disease, typhus and tick-borne relapsing fever, it’s important to predict outbreaks before they become a menace.

Rice University researchers are collaborating with Hotez and his team on a project that combines climate science and metagenomics to access 3,000 insect genomes. The goal is to aid health departments in controlling disease and informing policy.

The Hill Prize, which is being awarded to six innovators for the first time, thanks to a $10 million commitment from the philanthropic organization, is intended to back ideas that are high-risk and high-reward. Each of the projects was chosen for its potential real-life impact on some of Texas's — and the world’s — most challenging situations. Hotez’s prize is the first Hill Prize to be given in the realm of public health. The additional winners are:

  • Hill Prize in Medicine: Kenneth M. Hargreaves, D.D.S., Ph.D., The University of Texas Health Science Center at San Antonio
  • Hill Prize in Engineering: Joan Frances Brennecke, Ph.D. (NAE), The University of Texas at Austin
  • Hill Prize in Biological Sciences: David J. Mangelsdorf, Ph.D. (NAM, NAS), UT Southwestern Medical Center
  • Hill Prize in Physical Sciences: James Chelikowsky, Ph.D., The University of Texas at Austin
  • Hill Prize in Technology: Robert De Lorenzo, M.D., EmergenceMed, LLC
Read about other Houston-area researchers recognized by TAMEST here.

How Houston's cost of living compares to other major Texas cities in 2025

Calculating Costs

A new cost-of-living index yields a result that many Houstonians will find surprising: Houston is not the most expensive place to live in Texas. Dallas and Austin are costlier.

Numbeo’s cost-of-living index for 2025 shows Dallas ranks first in Texas and 24th in North America, landing at 65.8. The cost-of-living index compares the cost of living in New York City (which sits at 100) with the cost of living in another city. Austin is at 61.7, Houston at 60.6, and San Antonio at 58.8.

Houston ranks 40th overall in North America, out of 52 cities in the index.

Numbeo’s cost-of-living index takes into account the cost of items like groceries, restaurant meals, transportation, and utilities. The index excludes rent.

When rent is added to the cost-of-living index, Houston is still third among Texas cities. Dallas grabs the No. 21 spot in North America (57.1), one notch above Austin (56.6). Houston ranks 35th (51.4), and San Antonio ranks 42nd (34.6).

Rent index
While Dallas holds the top Texas spot on Numbeo’s overall cost-of-living index, Austin faces the highest rent prices. Numbeo's rent index for Austin sits at 50.1, putting it in 12th place among major cities in North America and highest in Texas, above the indexes for Dallas, Houston, and San Antonio. Houston lands at 27th.

The rent index in New York City, which tops the list, is 100. As Numbeo explains, the rent index estimates the cost of renting an apartment in a city compared with New York City. If the rent index is 50, for example, this suggests the average rent in that city is 50 percent below the average rent in New York City.

Around Texas, the rent index is:

  • 46.2 in Dallas
  • 39.8 in Houston
  • 34.6 in San Antonio

Restaurant index
In contrast to its showing on the rent and cost-of-living indexes, Houston outranks Dallas, Austin, and San Antonio on Numbeo’s restaurant index. This index compares the prices of meals and drinks at restaurants and bars to those in New York City.

Houston sits at No. 25 on the restaurant index, at 68.9. Dallas comes in at No. 32 (67.1), Austin at No. 34 (66.6), and San Antonio at No. 36 (65.2).

The National Restaurant Association reported in December that menu prices in the U.S. had risen 3.6 percent in the past 12 months, outpacing gains in grocery prices and the federal government’s overall Consumer Price Index. Fortunately for diners, that was the smallest 12-month increase in menu prices since August 2020, according to the association.

Toast, which provides a cloud-based restaurant management system, says the higher menu prices reflect higher food prices.

“Food prices have been increasing due to inflation, labor expenses, fuel costs, and supply chain disruptions, all of which impact restaurant profitability, Toast says. “While raising menu prices is one option to combat rising food costs, some restaurants have introduced service charges and simplified menus to avoid passing all costs onto customers.”

---

This story originally appeared on our sister site, CultureMap.com.

Houston startup taps strategic partner to produce novel 'biobased leather'

cleaner products

A Houston-based next-gen material startup has revealed a new strategic partnership.

Rheom Materials, formerly known as Bucha Bio, has announced a strategic partnership with thermoplastic extrusion and lamination company Bixby International, which is part of Rheom Material’s goal for commercial-scale production of its novel biobased material, Shorai.

Shorai is a biobased leather alternative that meets criteria for many companies wanting to incorporate sustainable materials. Shorai performs like traditional leather, but offers scalable production at a competitive price point. Extruded as a continuous sheet and having more than 92 percent biobased content, Shorai achieves an 80 percent reduction in carbon footprint compared to synthetic leather, according to Rheom.

Rheom, which is backed by Houston-based New Climate Ventures, will be allowing Bixby International to take a minority ownership stake in Rheom Materials as part of the deal.

“Partnering with Bixby International enables us to harness their extensive expertise in the extrusion industry and its entire supply chain, facilitating the successful scale-up of Shorai production,” Carolina Amin Ferril, CTO at Rheom Materials, says in a news release. “Their highly competitive and adaptable capabilities will allow us to offer more solutions and exceed our customers’ expectations.”

In late 2024, Rheom Materials started its first pilot-scale trial at the Bixby International facilities with the goal of producing Shorai for prototype samples.

"The scope of what we were doing — both on what raw materials we were using and what we were creating just kept expanding and growing," founder Zimri Hinshaw previously told InnovationMap.

Listen to Hinshaw on the Houston Innovators Podcast episode recorded in October.